Improving the understanding of how patients with non-dystrophic myotonia are selected for myotonia treatment with mexiletine (NaMuscla): outcomes of treatment impact using a European Delphi panel

BACKGROUND: Non-dystrophic myotonias (NDMs) comprise muscle chloride and sodium channelopathies due to genetic defects of the CLCN1- and SCN4A-channels. No licensed antimyotonic treatment has been available until approval of mexiletine (NaMuscla®) for adult patients by the EMA in December 2018. This...

Descripción completa

Detalles Bibliográficos
Autores principales: Chapman, Ann-Marie, Schurer, Marieke, Weijers, Laure, Omar, Amer, Lee, Hiba, Weidenfeller, Alla Zozulya, Ellis, Crispin, Sonecha, Shaneil, Schneider-Gold, Christiane
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8633892/
https://www.ncbi.nlm.nih.gov/pubmed/34852780
http://dx.doi.org/10.1186/s12883-021-02491-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8633892/
https://www.ncbi.nlm.nih.gov/pubmed/34852780
http://dx.doi.org/10.1186/s12883-021-02491-3

Ejemplares similares